These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 11767386)

  • 41. Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
    Johansen IS; Thomsen VØ; Marjamäki M; Sosnovskaja A; Lundgren B
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):103-7. PubMed ID: 15474318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Resistance of Mycobacterium tuberculosis to the major antitubercular drugs in pulmonary tuberculosis in children and youth previously untreated].
    Mordyński K; Piotrowski Z; Szymański A
    Gruzlica; 1968 Aug; 36(8):715-8. PubMed ID: 4972465
    [No Abstract]   [Full Text] [Related]  

  • 43. Recall of isoniazid used for antimicrobial susceptibility testing for tuberculosis.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Sep; 49(34):780-2. PubMed ID: 10987246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A study on prevalence of resistance to primary and secondary drugs among newly admitted pulmonary tuberculosis patients in 1977. Part 2. Studies on the factors related to the prevalence of drug resistance (author's transl)].
    Gomi J; Chiba Y; Yanagisawa K
    Kekkaku; 1979 Dec; 54(12):549-55. PubMed ID: 118299
    [No Abstract]   [Full Text] [Related]  

  • 45. [Factors relating to the incidence of drug resistance for anti-tuberculosis drugs during chemotherapy. 2].
    Yamamoto M
    Kekkaku; 1970 Nov; 45(11):359-66. PubMed ID: 4992936
    [No Abstract]   [Full Text] [Related]  

  • 46. Management and outcome of tuberculosis patients who fail treatment under routine programme conditions in Malawi.
    Harries AD; Nyirenda TE; Kemp JR; Squire BS; Godfrey-Faussett P; Salaniponi FM
    Int J Tuberc Lung Dis; 2003 Nov; 7(11):1040-4. PubMed ID: 14598962
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Studies of the polychemoresistance of Mycobacterium tuberculosis].
    Curci G; De Franciscis V; Giuliano V
    Arch Monaldi; 1970; 25(2):99-114. PubMed ID: 4994908
    [No Abstract]   [Full Text] [Related]  

  • 48. [Secondary drug sensitivity of tubercle bacilli in chronic sputum-positive tuberculosis patients].
    Telejko Z
    Gruzlica; 1970 Oct; 38(11):1101-4. PubMed ID: 4992233
    [No Abstract]   [Full Text] [Related]  

  • 49. [Drug resistance of tubercle bacilli isolated from sputum in previously untreated pulmonary tuberculosis. 3].
    Nakai H; Maekawa N; Nakanishi M; Kawai M; Naito M
    Bull Chest Dis Res Inst Kyoto Univ; 1971 Jan; 4(1):15-24. PubMed ID: 5005481
    [No Abstract]   [Full Text] [Related]  

  • 50. [Resistance and virulence of mycobacteria. Clinical and experimental studies].
    Lucchesi M
    Ftiziologia; 1971; 20(4):401-4. PubMed ID: 5005707
    [No Abstract]   [Full Text] [Related]  

  • 51. [Evaluation of new antitubercular agents--new quinolones].
    Kawahara S; Eirei J
    Kekkaku; 1992 Oct; 67(10):679-82. PubMed ID: 1453572
    [No Abstract]   [Full Text] [Related]  

  • 52. [Primary resistance in the area of the District of Split].
    Giunio N
    Plucne Bolesti; 1986; 38(2):144-6. PubMed ID: 3097689
    [No Abstract]   [Full Text] [Related]  

  • 53. [Incidence of drug resistance of Mycobacterium tuberculosis].
    Terentieva AS
    Vrach Delo; 1979 Mar; (3):28-30. PubMed ID: 109992
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinical aspects of secondary resistance in pulmonary tuberculosis].
    Gugić B
    Plucne Bolesti; 1985; 37(1-2):22-7. PubMed ID: 3934690
    [No Abstract]   [Full Text] [Related]  

  • 55. [Dynamics of the frequency of development of drug resistance in the causative agent of tuberculosis and its effect on the efficacy of treatment of patients with pulmonary tuberculosis].
    Abramovskaia AK; Antipova SI
    Probl Tuberk; 1988; (10):24-7. PubMed ID: 3148132
    [No Abstract]   [Full Text] [Related]  

  • 56. [Factors affecting the efficacy of the treatment of tuberculosis patients discharging drug-resistant mycobacteria].
    Fomicheva NI; Terentieva AS
    Probl Tuberk; 1981 Dec; (12):23-6. PubMed ID: 6801645
    [No Abstract]   [Full Text] [Related]  

  • 57. [Epidemiologic aspects of resistance to ATA (Antitubercular Agents)].
    Zrilić V; Muzikravić T
    Plucne Bolesti Tuberk; 1974; 26 Suppl 2():29-37. PubMed ID: 4216919
    [No Abstract]   [Full Text] [Related]  

  • 58. Susceptibilities of Mycobacterium tuberculosis to isoniazid and rifampin on blood agar.
    Coban AY; Bilgin K; Uzun M; Tasdelen Fisgin N; Akgunes A; Cihan CC; Birinci A; Durupinar B
    J Clin Microbiol; 2005 Apr; 43(4):1930-1. PubMed ID: 15815022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expanding the role of the microscopic observation drug susceptibility assay in tuberculosis and HIV management.
    Minion J; Pai M
    Clin Infect Dis; 2010 Apr; 50(7):997-9. PubMed ID: 20192726
    [No Abstract]   [Full Text] [Related]  

  • 60. [Possibility of the intensification of tuberculosis chemotherapy and its limits].
    Naito M; Kanai K; Kondo E; Yamashita H; Matsui K
    Kekkaku; 1969 Nov; 44(11):377-93. PubMed ID: 4982567
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.